Martin Shkreli on Drug Pricing, Prison, and the Fraud That Shook Pharma
About this episode
Martin Shkreli discusses drug pricing, patent law, and the pharmaceutical industry with hosts Anish Koka and Anthony DiGiorgio.
Episode Summary Anish Koka and Anthony DiGiorgio sit down with Martin Shkreli — the former hedge fund manager and pharma executive best known for the 2015 Daraprim price increase and his subsequent prison sentence — for a wide-ranging conversation on drug pricing, patent law, and the state of the pharmaceutical industry. Shkreli walks through his path from a teenage hedge fund intern to founding Retrophin and Turing Pharmaceuticals, defends orphan drug economics and the Orphan Drug Act's seven-year exclusivity window, and argues that patent terms haven't kept pace with the realities of modern drug development. The conversation turns to the Chemocentrics/Amgen scandal — in which trial data for a rare vasculitis drug was allegedly unblinded, manipulated, and relocked to manufacture statistical significance — which Shkreli calls one of the worst frauds in the history of medicine. The episode closes with discussion of the Sarepta/DMD approval controversy, the limits of randomized trials in surgery and rare disease, AI's parallels to neuroscience, and the state of media coverage of the FDA. Chapter Markers 00:00 Intro and Martin Shkreli's backstory 02:40 Origin story: from hedge fund…
More episodes of The Doctor's Lounge
- Cremieux on FDA Reform, Fake Data, and the Columbia Admissions Hack
- Scott Becker on Building Becker's Healthcare, Physician Supply, and Private Enterprise
- Do No Harm: Inside the Fight to Get Identity Politics Out of Medicine
- The Myocarditis Double Standard: COVID, the Vaccine, and the Pediatric Deaths That Went Unreported
- David Zweig on Schools, Science, and the Media's COVID Failure
- Drug Pricing, Broken Incentives, and the 340b program Fixes Washington Won't Touch
Explore listener stats, chart rankings, contacts and more on the The Doctor's Lounge podcast page.